536 related articles for article (PubMed ID: 31147173)
21. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
22. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.
Al-Hadidi SA; Lee HJ
JCO Oncol Pract; 2021 Feb; 17(2):64-71. PubMed ID: 33434064
[TBL] [Abstract][Full Text] [Related]
24. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
25. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
[TBL] [Abstract][Full Text] [Related]
26. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
27. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
Steinerová K; Jindra P; Lysák D; Karas M
Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
29. How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.
Mei M; Chen R
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):26-33. PubMed ID: 29233742
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
Zhao L; Yang Y; Li W; Li T; Gao Q
Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
[TBL] [Abstract][Full Text] [Related]
31. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
[TBL] [Abstract][Full Text] [Related]
32. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
Fernández KS; Mavers M; Marks LJ; Agarwal R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
[TBL] [Abstract][Full Text] [Related]
35. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
36. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.
Lepik KV; Mikhailova NB; Moiseev IS; Kondakova EV; Tsvetkova LA; Zalyalov YR; Borzenkova ES; Babenko EV; Baykov VV; Markova IV; Afanasyev BV
Leuk Lymphoma; 2019 Sep; 60(9):2316-2319. PubMed ID: 30712423
[No Abstract] [Full Text] [Related]
38. Novel treatment concepts in Hodgkin lymphoma.
Glimelius I; Diepstra A
J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
[TBL] [Abstract][Full Text] [Related]
39. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
[TBL] [Abstract][Full Text] [Related]
40. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Moskowitz AJ; Herrera AF; Beaven AW
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
